AstraZeneca expects vaccine data this year, sales beat estimates
[FRANKFURT] AstraZeneca, the British drugmaker working on one of the world's leading Covid-19 vaccine candidates, on Thursday beat third-quarter sales estimates as demand for its diverse portfolio of drugs remained strong during Covid-19 pandemic lockdowns, and it maintained its 2020 forecasts.
The company reiterated it expected results from the late-stage trials on its experimental Covid-19 vaccine later this year, depending on the rate of infection among trial participants.
Product sales, which exclude payments from collaborations, rose 7 per cent to US$6.52 billion for the three months ended Sept 30 on a constant-currency basis, ahead of a company-compiled consensus of US$6.50 billion.
However, the company reported core earnings of 94 US cents per share, lower than analysts' expectations of 98 cents.
REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Jim Beam owner bets on canned vodka cocktails to double revenue
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Cordlife served letter of demand, notice of claim from customers
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs